You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • SAT0110 Efficacy and Safety of Pateclizumab (Anti-Lymphotoxin-Alpha) in Dmard-Ir Patients: Results of a Randomized, Double-Blind, Placebo-Controlled Head-To-Head Phase 2 Study with Adalimumab

Article metrics

Article menu
Download PDFPDF
Scientific Abstracts
Rheumatoid arthritis - other biologictreatment
SAT0110 Efficacy and Safety of Pateclizumab (Anti-Lymphotoxin-Alpha) in Dmard-Ir Patients: Results of a Randomized, Double-Blind, Placebo-Controlled Head-To-Head Phase 2 Study with Adalimumab

 

Online download statistics by month:

Online download statistics by month: February 2014 to March 2024

AbstractFullPdf
Feb 2014602
Mar 2014200
Apr 2014100
May 2014800
Jul 2014100
Oct 2014301
Nov 2014501
Dec 2014600
Jan 2015400
Feb 2015400
Mar 2015501
Apr 2015400
Jul 2015400
Aug 2015500
Sep 2015301
Nov 2015800
Dec 2015901
Jan 2016700
Mar 2016803
Apr 2016400
Jun 2016400
Jul 2016701
Aug 2016600
Sep 2016902
Oct 2016601
Nov 2016701
Dec 2016700
Jan 2017800
Feb 2017900
Mar 2017900
Apr 2017500
May 2017400
Jun 2017401
Jul 20171000
Aug 20171600
Sep 20171200
Oct 20171800
Nov 20171200
Dec 20173200
Jan 20181400
Feb 20182600
Mar 20182800
Apr 20184000
May 20189400
Jun 20183200
Jul 20182201
Aug 2018800
Sep 20181800
Oct 20182200
Nov 20184600
Dec 20182200
Jan 20191000
Feb 20191600
Mar 2019601
Apr 2019200
Jul 20193000
Aug 20194800
Sep 20191400
Oct 2019800
Nov 20192100
Dec 20193000
Jan 20201400
Feb 2020600
Jun 2020500
Jul 2020800
Aug 2020600
Sep 20201500
Oct 2020400
Nov 2020500
Dec 2020400
Jan 2021600
Jun 2021500
Aug 2021100
Oct 2021500
Nov 2021200
Dec 20211401
Jan 2022200
Feb 20222401
Mar 20221400
May 2022200
Jun 2022100
Jul 20221200
Aug 20221400
Sep 2022600
Oct 20221400
Nov 2022400
Dec 2022800
Feb 2023200
Mar 2023400
May 2023400
Jun 20231403
Jul 2023500
Aug 2023400
Sep 2023800
Oct 2023200
Nov 2023200
Dec 20233202
Mar 2024200
Total1119025